Pillai, Jagan A.
Larvie, Mykol
Chen, Jacqueline
Crawford, Anna
Cummings, Jeffery L.
Jones, Stephen E.
Funding for this research was provided by:
NIH (NIA K23AG055685-01)
Article History
Received: 9 June 2020
Accepted: 11 November 2020
First Online: 26 November 2020
Competing interests
: J.A.P. has received research funding from the National Institutes of Health (NIH), Alzheimer’s Association, and Keep Memory Alive. M.L. has received research funding from NIH. J.C. is a consultant to Acadia, Accera, Actinogen, Agenebio, Alkahest, Allergan, Alzheon, Annovis, Avanir, Axsome, Cassava, Cerevel, Cortexyme, EIP Pharma, Eisai, Foresight, Green Valley, Grifols, Karuna, Nutricia, Otsuka, ReMYND, Resverlogix, Roche, Samus, Samumed, Sunovion, Suven, Third Rock, and United Neuroscience pharmaceutical and assessment companies and has received research funding from the National Institute of General Medical Sciences (Grant: P20GM109025) and Keep Memory Alive. S.E.J. has received research funding from NIH, St Jude, and Biogen; has received speaking fees from Siemens, Radnet, and St Jude’s Hospital; and is a consultant to Eisai and Monteris. A.C. and J.L.C. have no potential conflicts of interest to declare. “Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number K23AG055685. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”